cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Ac Immune Sa
47 own
33 watching
Current Price
$2.85
$-0.05
(-1.72%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
185.32M
52-Week High
52-Week High
3.83000
52-Week Low
52-Week Low
1.68000
Average Volume
Average Volume
0.03M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
9.8528
iconMarket Capitalization185.32M
icon52-Week High3.83000
icon52-Week Low1.68000
iconAverage Volume0.03M
iconDividend Yield--
iconP/E Ratio9.8528
What does the Ac Immune Sa do?
AC Immune SA is a biopharmaceutical company. It is engaged in leveraging its two proprietary technology platforms to discover, design and develop novel, proprietary medicines for treatment of neurodegenerative diseases.
Read More
News & Events about Ac Immune Sa.
Globe Newswire
3 months ago
AC Immune Showcasing Precision Medicine Programs at AAIC 2023 Lausanne, Switzerland, July 3, 2023 AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced upcoming presentations at the annual Alzheimers ...
Globe Newswire
5 months ago
AC Immune Reports First Quarter 2023 Financial Results and Provides a Corporate Update ACI-24.060 anti-Abeta vaccine showed positive initial safety and immunogenicity in first Alzheimers disease (AD) cohort in ABATE Phase 1b/2 trial;Further ABATE immunogenicity and safety data in higher dose AD ...
Globe Newswire
6 months ago
AC Immune at AD/PD 2023 to Present New Clinical and Preclinical Data from its Precision Medicine Pipeline Ten presentations at the International Conference on Alzheimers & Parkinsons Diseases (AD/PDTM)AC Immunes Chief Medical Officer to participate in expert forum on immunotherapies in Alzheimers ...
Globe Newswire
6 months ago
AC Immune Reports Full Year 2022 Financial Results and Provides Corporate Update Clinical-stage vaccine programs targeting amyloid-beta (Abeta), phosphorylated-Tau (pTau), and alpha-synuclein (a-syn) are all on track to reach important milestones in 2023ACI-24.060 anti-amyloid-beta vaccine for ...
Globe Newswire
6 months ago
AC Immune to Report Full Year 2022 Financial Results and Provide Corporate Update on March 16, 2023 Lausanne, Switzerland, March 8, 2023 AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that it will ...
Frequently Asked Questions
Frequently Asked Questions
What is Ac Immune Sa share price today?
plus_minus_icon
Can Indians buy Ac Immune Sa shares?
plus_minus_icon
How can I buy Ac Immune Sa shares from India?
plus_minus_icon
Can Fractional shares of Ac Immune Sa be purchased?
plus_minus_icon
What are the documents required to start investing in Ac Immune Sa stocks?
plus_minus_icon
What is today’s traded volume of Ac Immune Sa?
plus_minus_icon
What is today’s market capitalisation of Ac Immune Sa?
plus_minus_icon
What is the 52-Week High and Low Range of Ac Immune Sa?
plus_minus_icon
What percentage is Ac Immune Sa down from its 52-Week High?
plus_minus_icon
What percentage is Ac Immune Sa up from its 52-Week Low?
plus_minus_icon
Current Price
$2.85
$-0.05
(-1.72%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
KINNATE BIOPHARMA INC
KINNATE BIOPHARMA INC
$1.40
$0.02 (1.45 %)
CUE BIOPHARMA INC
CUE BIOPHARMA INC
$2.30
$-0.02 (-0.86 %)
Fulcrum Therapeutics Inc
Fulcrum Therapeutics Inc
$4.42
$-0.04 (-1.01 %)
Annexon Inc
Annexon Inc
$2.36
$0.07 (3.06 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
KINNATE BIOPHARMA INC
KINNATE BIOPHARMA INC
$1.40
$0.02 (1.45 %)
CUE BIOPHARMA INC
CUE BIOPHARMA INC
$2.30
$-0.02 (-0.86 %)
Fulcrum Therapeutics Inc
Fulcrum Therapeutics Inc
$4.42
$-0.04 (-1.01 %)
Annexon Inc
Annexon Inc
$2.36
$0.07 (3.06 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Foreside Fund Services acts as the distributor to the DriveWealth ICE 100 Index ETF and is not affiliated with Borderless Investing Inc, DriveWealth LLC, BlackOak Investors LP, ACR Group, or other entities referenced on this website.

              Get Started with as little as $1.00